Beruflich Dokumente
Kultur Dokumente
com
Sara F Forman, MD
UpToDate performs a continuous review of over 375 journals and other resources.
Updates are added as important new information is published. The literature review
for version 15.1 is current through December 2006; this topic was last changed on
January 2, 2007. The next version of UpToDate (15.2) will be released in June 2007.
The treatment and outcome of anorexia nervosa and bulimia nervosa are reviewed
here. The epidemiology, pathogenesis, and clinical features of eating disorders are
discussed separately. (See "Eating disorders: Epidemiology, pathogenesis, and clinical
features").
For patients with bulimia nervosa, a meta-analysis and systematic review both
concluded that cognitive behavioral therapy, other psychotherapies, antidepressant
medication, and combination treatment with an antidepressant and psychotherapy
are all likely to be beneficial [1,2]. A combination of antidepressants and
psychological treatment provided the best chance for remission. The American
Psychiatric Association (APA) Guidelines state that a combination of
psychotherapeutic intervention plus medications should be considered when initiating
treatment for patients with this disorder [3]. The Society for Adolescent Medicine has
also published specific treatment guidelines for adolescents with eating disorders [4].
For patients with binge eating disorder, dietary approaches, psychiatric therapy such
as interpersonal psychotherapy and CBT, and pharmacotherapy with
antidepressants, appetite suppressants, and antiepileptics have all been used with
encouraging results at least in the short term [5,6]. In addition to management of
the eating disorder, obese patients with binge eating disorder need to be evaluated
and treated for the physical morbidities associated with obesity (eg, diabetes, sleep
apnea, hyperlipidemia, cardiovascular disease, etc.).
Interdisciplinary care team — The most accepted treatment for eating disorders
involves an interdisciplinary team approach. This team should include a medical
provider, dietitian (with experience in treating eating disorders), and a mental health
professional.
Medical provider — The medical provider works to manage medical concerns such as
vital sign stability, electrolyte abnormalities, and hydration status, and can also act
as the coordinator of care. Often weekly weigh-in and vital sign checks are needed to
ensure weight gain and medical stability. Long-term sequelae, including issues
related to bone denisty issues, menstrual cycles, and growth issues in younger
patients, also need to be followed.
Dietitian — The dietitian plays a major role by providing nutritional education about
a healthy diet and the rationale for making changes in eating behaviors. The dietitian
also engages in concrete dialogue with the patient surrounding available meal or
dietary options and gives specific caloric or meal plan requirements. The dietitian can
help the medical provider to plan the appropriate weight goals for the patient.
Mental health provider — The third and critical part of the care team is a mental
health provider. Individual and cognitive behavioral therapy are the mainstays of
treatment for eating disorders, as is family involvement in therapy. These
approaches help the patient to work on underlying issues that may have initiated the
eating disorder. A therapist with experience and expertise in the treatment of eating
disorder patients is essential. Much of the psychological work will not focus upon the
eating behaviors per se, but on the affective issues that surround the eating
disorder. The mental health provider may also help guide the other team members
on the underlying or concurrent mental health issues, severity of the case, and the
need for psychiatric hospitalization or day treatment programs. Patients with eating
disorders appear to be at increased risk for self-injurious behavior, and this
propensity should be a part of the routine assessment of these individuals [7].
Nutritional therapy — The American Psychiatric Association (APA) Guidelines for the
treatment of patients with eating disorders state that a program of nutritional
rehabilitation should be established for all patients with anorexia nervosa who are
underweight [3]. Expected rates of controlled weight gain are 2 to 3 pounds (0.9 to
1.4 kg) per week for most inpatients and 0.5 to 1 pound (0.2 to 0.5 kg) per week for
most outpatients. Intake levels usually begin at 30 to 40 kcal/kg (1000 to 1600
kcal/day) and are advanced progressively. For patients with bulimia nervosa, the
guidelines state that nutritional counseling may be a useful adjunct to other
treatment modalities.
Patients may gain weight rapidly early in the refeeding process because of fluid
retention and a baseline low metabolic rate [8,9]. The number of calories required
increases considerably with weight gain.
In patients with binge eating disorder and obesity, dietary approaches, including very
low calorie diets, may be of benefit in reducing binge eating, but they appear to have
only limited efficacy in reducing weight [5].
Refeeding syndrome — Patients with severe anorexia nervosa (ie, less than 75
percent of ideal body weight) and those who have lost a large amount of weight
rapidly are at risk for the refeeding syndrome during the first two to three weeks of
refeeding [9,10]. Patients with severe weight loss who are rapidly refed are at
greatest risk. Patients with recent rapid weight loss, as well as patients who have
had prolonged weight loss, may also be at increased risk.
Although there are not good data to support this practice, some physicians will treat
patients with phosphorous replacement during the initial phases of refeeding. This is
acceptable management as long as the patient has adequate renal function, and it
may help to avoid the hypophosphatemia associated with refeeding. Others,
however, recommend refraining from phosphate supplementation until
hypophosphatemia is diagnosed with close laboratory surveillance [12].
Psychotherapy
The evidence of efficacy of CBT for anorexia nervosa is more limited. A 20-week
randomized trial in 56 women with anorexia nervosa that compared CBT,
interpersonal therapy, and a control treatment of nonspecific supportive clinical
management found that on the primary global outcome measure, supportive clinical
management was significantly superior to interpersonal therapy and was probably
also superior to CBT [20]. These results may have important implications for the
management of anorexia nervosa but must be confirmed in other trials.
Binge eating disorder appears to respond to CBT, at least in the short term, although
the effects wane over time [5]. CBT has only limited efficacy in promoting sustained
weight loss.
The Maudsley method, incorporating family therapy, has also shown promising
results [22]. This therapy encourages parents to refeed their children at home with
the support of a family therapist. Parents are placed in charge of the actual feeding
regimen of the affected child.
Medication
The largest randomized trial, published subsequent to the systematic review, found
no difference in time to relapse or maintenance of BMI 18.5 comparing patients
who were randomly assigned, after completion of an in-hospital program, to receive
fluoxetine (n = 49) or placebo (n = 44) for 52 weeks [25]. Patients in both groups
were concurrently treated with cognitive behavioral therapy, which may in part
explain why these results differ from an earlier and smaller placebo trial that did
demonstrate effectiveness of fluoxetine in weight maintenance [26]. In the latter
study, patients in the placebo arm did not receive standardized psychosocial therapy
and had a relatively high relapse rate. It should be emphasized that these studies
were designed to evaluate the effect of fluoxetine on eating behaviors and weight
maintenance; use of fluoxetine or other antidepressants to manage depression in
patients with eating disorders should not be altered, based on these results.
Anxiolytic medications may be helpful before meals for the anorexic patient who is
having anxiety before eating. There are case reports in the literature of the
successful use of olanzapine in patients with severe anorexia nervosa. The APA
guidelines state that psychotropic medications should not be used as the sole or
primary treatment for anorexia nervosa, but they can be considered for the
prevention of relapse in weight restored patients or to treat depression or obsessive
compulsive disorder [3].
Two other drugs that may be useful in patients with bulimia nervosa are the
antiepileptic agent topiramate and the selective serotonin antagonist ondansetron:
Further study of both of these agents is necessary before they can be considered
treatment options in patients with bulimia nervosa.
Other drugs that have been investigated for the treatment of bulimia nervosa include
lithium and naltrexone; neither has shown to be of significant benefit [35,38].
Hospitalization — There have been no controlled trials that have evaluated criteria
for hospitalization in patients with eating disorders. The Society for Adolescent
Medicine (SAM) has published guidelines for hospitalization; one or more of the
following justify hospitalization [4]:
• Severe malnutrition (weight less than 75 percent of average body weight for
age, sex, and height)
• Dehydration
• Electrolyte disturbances (hypokalemia, hyponatremia, hypophosphatemia)
• Cardiac dysrhythmia
• Physiologic instability (severe bradycardia [heart rate less than 50 beats per
minute during the day or less than 45 at night], hypotension [less than 80/50
mmHg], hypothermia [less than 96ºF], orthostatic changes in pulse [more than 20
beats per minute] or blood pressure [more than 10 mmHg])
• Arrested growth and development
• Failure of outpatient treatment
• Acute food refusal
• Uncontrollable binging and purging
• Acute medical complication of malnutrition (eg, syncope, seizures, cardiac
failure, pancreatitis, etc.)
• Acute psychiatric emergencies (eg, suicidal ideation, acute psychosis)
• Comorbid diagnosis that interferes with the treatment of eating disorders (eg,
severe depression, obsessive compulsive disorder, severe family dysfunction)
More recent APA guidelines present other criteria for hospitalization (show table 1).
[3]. The APA emphasizes that the decision to hospitalize should be based upon
psychiatric, behavioral, and general medical factors, and provides the following
indications, with specific parameters for adults and children/adolescents:
Recovery is difficult without an added level of support when in a low weight range.
Hospitalization can be on either a medical or psychiatric ward, depending upon the
age and medical status of the patient and local resources. The hospital unit must be
experienced with the care and refeeding of the anorexic patient and have guidelines
or a protocol. Patients may be resistant to being refed. Thus, nurses who are
sensitive yet able to set limits and enforce eating requirements are a key in the
success of the hospitalization.
One study examined outcomes after hospitalization and found that those eating
disordered patients who were allowed to remain in the hospital until they had
regained their necessary weight (90 to 92 percent of ideal body weight) had a much
improved outcome compared with those who did not regain their weight and were
discharged earlier [40]. As well, longer initial hospitalization has been shown to be
cost-effective [41]. These findings suggest that prolonged initial hospitalizations may
provide the support necessary to successfully treat patients with eating disorders.
When referring patients for inpatient treatment, providers should be aware that the
range of treatments is quite varied with some programs using oral liquid nutrition,
nasogastric tube feedings, or gradual caloric increase with "regular" food. Parenteral
nutrition is almost never indicated. Providers should become familiar with the
treatment options available in their area.
• Growth factors such as IGF-I may have short-term effects upon bone
formation in women with anorexia nervosa [42]; the long-term effects of this therapy
are unknown.
Recommendations from the Society for Adolescent Medicine include weight gain,
1200 to 1500 mg/day of elemental calcium, and a multivitamin providing 400 IU of
vitamin D [4]. Individual assessments for estrogen/progestin replacement in women
may be considered. Dual emission X-Ray Absorptiometry (DEXA) scan at the initial
medical assessment of a patient with an eating disorder and at varying intervals
every 6 to 12 months can assist in counseling those at high risk for fractures and
bone loss. Care should be taken in counseling regarding exercise recommendations.
(See "Clinical manifestations and diagnosis of osteoporosis").
Summary
• Patients with bulimia nervosa may also benefit from pharmacologic therapy,
particularly with the selective serotonin reuptake inhibitors such as fluoxetine.
• Patients with anorexia nervosa are at risk for osteopenia. Treatment includes
weight gain and daily supplementation with 1200 to 1500 mg of elemental calcium
plus a multivitamin containing 400 IU of vitamin D. Estrogen/progestin replacement
may be appropriate in selected women.
A number of patients with anorexia nervosa have a bulimic phase during their
recoveries. Poor outcomes are associated with later age of onset of the eating
disorder, longer duration of the illness, and lower minimal weight [4]. Overall, 32 to
70 percent recover fully at 20 years of follow-up; those who do not may have
increased psychiatric comorbidity [50-52].
A focus only on treating weight issues may leave many anorexia nervosa patients
with persisting psychological problems. This was illustrated in a case-control study of
70 women with this disorder [55]. A minority of the patients (10 percent) continued
to meet the criteria for anorexia nervosa at a mean of 12 years after initial referral to
an eating disorders service. Even among those who no longer met these criteria,
relatively low body weight and cognitive features characteristic of anorexia nervosa
(perfectionism and cognitive restraint) persisted. The rates of lifetime comorbid
major depression, alcohol dependence, and a number of anxiety disorders were very
high.
One study that examined the follow-up of bulimia patients found that the number of
women who continued to meet the full criteria for bulimia nervosa declined as the
duration of follow-up increased [56]. However, 30 percent continued to engage in
recurrent binging and purging behaviors over approximately 10 years of follow-up.
Substance abuse and long duration of the disorder were poor prognostic signs.
Mortality — There is significant mortality associated with anorexia nervosa. One 10-
year follow-up study found an overall mortality rate of 6.6 percent [57]. Similar
findings were noted in a meta-analysis that examined 42 outcome studies between
1920 and 1980: the overall mortality rate was 0.56 percent per year [58]. Young
women with anorexia nervosa had a 10-fold increase in mortality compared with
women who were unaffected. Causes of death in the meta-analysis included
complications of the eating disorder (54 percent), suicide (27 percent), and unknown
or other causes (19 percent).
Most of the follow-up studies that assessed mortality were for referral-based care to
an eating disorders center or hospital; as a result, they may reflect a sicker
population of cases. In contrast, a population-based study of 208 patients (193
women and 15 men, median follow-up 22 years) diagnosed with anorexia nervosa in
Minnesota found a trend toward a decrease in mortality (standardized mortality ratio
0.71, 95% CI 0.42-1.09) [59]. Although the numbers are small, a decrease in deaths
from cardiovascular disease may have offset deaths due to anorexia and related
comorbidities (such as depression, alcoholism, and pneumonia) [60].
REFERENCES
1. Whittal, ML, Agras, WS, Gould, RA. Bulimia nervosa: A meta-analysis of
psychosocial and pharmacological treatments. Behav Ther 1999; 30:117.
2. Bacaltchuk, J, Hay, P, Trefiglio, R. Antidepressants versus psychological treatments
and their combination for bulimia nervosa. Cochrane Database Syst Rev 2001;
:CD003385.
3. American Psychiatric Association. Practice guideline for the treatment of patients
with eating disorders, third edition. Am J Psychiatry 2006; 163 Suppl 1:1.
4. Golden, NH, Katzman, DK, Kreipe, RE, et al. Eating disorders in adolescents:
position paper of the Society for Adolescent Medicine. J Adolesc Health 2003;
33:496.
5. Wonderlich, SA, de Zwaan, M, Mitchell, JE, et al. Psychological and dietary
treatments of binge eating disorder: conceptual implications. Int J Eat Disord 2003;
34 Suppl:S58.
6. Carter, WP, Hudson, JI, Lalonde, JK, et al. Pharmacologic treatment of binge eating
disorder. Int J Eat Disord 2003; 34 Suppl:S74.
7. Paul, T, Schroeter, K, Dahme, B, Nutzinger, DO. Self-injurious behavior in women
with eating disorders. Am J Psychiatry 2002; 159:408.
8. Platte, P, Pirke, KM, Trimborn, P, et al. Resting metabolic rate and total energy
expenditure in acute and weight recovered patients with anorexia nervosa and in
healthy young women. Int J Eat Disord 1994; 16:45.
9. Mehler, PS. Diagnosis and Care of Patients with Anorexia Nervosa in Primary Care
Settings. Ann Intern Med 2001; 134:1048.
10. Solomon, SM, Kirby, DF. The refeeding syndrome: a review. JPEN J Parenter Enteral
Nutr 1990; 14:90.
11. Hearing, SD. Refeeding syndrome. BMJ 2004; 328:908.
12. Ornstein, RM, Golden, NH, Jacobson, MS, Shenker, IR. Hypophosphatemia during
nutritional rehabilitation in anorexia nervosa: implications for refeeding and
monitoring. J Adolesc Health 2003; 32:83.
13. Kamal, N, Chami, T, Andersen, A, et al. Delayed gastrointestinal transit times in
anorexia nervosa and bulimia nervosa. Gastroenterology 1991; 101:1320.
14. Stacher, G. Gut function in anorexia nervosa and bulimia nervosa. Scand J
Gastroenterol 2003; 38:573.
15. Lewandowski, LM, Geging, TA, Anthony, JL, O'Brien, WH. Meta-analysis of cognitive-
behavioral treatment studies for bulimia. Clin Psychol Rev 1997; 17:703.
16. Garner, DM, Garfinkel, PE. Handbook of treatment for eating disorders, 2nd ed,
Guilford Press, New York 1997.
17. Fairburn, CG, Norman, PA, Welch, SL, et al. A prospective study of outcome in
bulimia nervosa and the long-term effects of three psychological treatments. Arch
Gen Psychiatry 1995; 52:304.
18. Agras, WS, Walsh, T, Fairburn, CG, et al. A multicenter comparison of cognitive-
behavioral therapy and interpersonal psychotherapy for bulimia nervosa. Arch Gen
Psychiatry 2000; 57:459.
19. McIntosh, VV, Jordan, J, Carter, FA, et al. Three psychotherapies for anorexia
nervosa: a randomized, controlled trial. Am J Psychiatry 2005; 162:741.
20. Wilfley, DE, Welch, RR, Stein, RI, et al. A randomized comparison of group
cognitive-behavioral therapy and group interpersonal psychotherapy for the
treatment of overweight individuals with binge-eating disorder. Arch Gen Psychiatry
2002; 59:713.
21. J Am Acad Child Adolesc Psychiatry 2005; 44:632.
22. Jimerson, DC, Wolfe, BE, Brotman, AW, Metzger, ED. Medications in the treatment
of eating disorders. Psychiatr Clin North Am 1996; 19:739.
23. Claudino, A, Hay, P, Lima, M, et al. Antidepressants for anorexia nervosa. Cochrane
Database Syst Rev 2006; :CD004365.
24. Walsh, BT, Kaplan, AS, Attia, E, et al. Fluoxetine after weight restoration in anorexia
nervosa: a randomized controlled trial. JAMA 2006; 295:2605.
25. Kaye, WH, Nagata, T, Weltzin, TE, et al. Double-blind placebo-controlled
administration of fluoxetine in restricting- and restricting-purging-type anorexia
nervosa. Biol Psychiatry 2001; 49:644.
26. Bacaltchuk, J, Hay, P. Antidepressants versus placebo for people with bulimia
nervosa (Cochrane Review). Cochrane Database Syst Rev 2001; 4:CD003391.
27. Goldstein, DJ, Wilson, MG, Thompson, VL, et al. Long-term fluoxetine treatment of
bulimia nervosa. Br J Psychiatry 1995; 166:660.
28. Walsh, BT, Wilson, GT, Loeb, KL, et al. Medication and psychotherapy in the
treatment of bulimia nervosa. Am J Psychiatry 1997; 154:523.
29. Fluoxetine in the treatment of bulimia nervosa. A multicenter, placebo-controlled,
double-blind trial. Fluoxetine Bulimia Nervosa Collaborative Study Group. Arch Gen
Psychiatry 1992; 49:139.
30. Hughes, PL, Wells, LA, Cunningham, CJ, Ilstrup, DM. Treating bulimia with
desipramine. A double-blind, placebo-controlled study. Arch Gen Psychiatry 1986;
43:182.
31. Pope, HG Jr, Hudson, JI, Jonas, JM, Yurgelun-Todd, D. Bulimia treated with
imipramine: A placebo-controlled, double-blind study. Am J Psychiatry 1983;
140:554.
32. Mitchell, JE, Groat, R. A placebo-controlled, double-blind trial of amitriptyline in
bulimia. J Clin Psychopharmacol 1984; 4:186.
33. Horne, RL, Ferguson, JM, Pope, HG Jr, et al. Treatment of bulimia with bupropion: A
multicenter controlled trial. J Clin Psychiatry 1988; 49:262.
34. Hsu, LK, Clement, L, Santhouse, R, Ju, ES. Treatment of bulimia nervosa with
lithium carbonate. A controlled study. J Nerv Ment Dis 1991; 179:351.
35. McElroy, SL, Arnold, LM, Shapira, NA, et al. Topiramate in the treatment of binge
eating disorder associated with obesity: a randomized, placebo-controlled trial. Am J
Psychiatry 2003; 160:255.
36. Faris, PL, Kim, SW, Meller, WH, et al. Effect of decreasing afferent vagal activity with
ondansetron on symptoms of bulimia nervosa: a randomised, double-blind trial.
Lancet 2000; 355:792.
37. Mitchell, JE, Christenson, G, Jennings, J, et al. A placebo-controlled, double-blind,
crossover study of naltrexone hydrochloride in outpatients with normal weight
bulimia. J Clin Psychopharmacol 1989; 9:94.
38. Arnold, LM, McElroy, SL, Hudson, JI, et al. A placebo-controlled, randomized trial of
fluoxetine in the treatment of binge-eating disorder. J Clin Psychiatry 2002;
63:1028.
39. Appolinario, JC, Bacaltchuk, J, Sichieri, R, et al. A randomized, double-blind,
placebo-controlled study of sibutramine in the treatment of binge-eating disorder.
Arch Gen Psychiatry 2003; 60:1109.
40. Baran, SA, Weltzin, TE, Kaye, WH. Low discharge weight and outcome in anorexia
nervosa. Am J Psychiatry 1995; 152:1070.
41. Crow, SJ, Nyman, JA. The cost-effectiveness of anorexia nervosa treatment. Int J
Eat Disord 2004; 35:155.
42. Grinspoon, S, Herzog, D, Klibanski, A. Mechanisms and treatment options for bone
loss in anorexia nervosa. Psychopharmacol Bull 1997; 33:399.
43. Golden, NH, Iglesias, EA, Jacobson, MS, et al. Alendronate for the treatment of
osteopenia in anorexia nervosa: a randomized, double-blind, placebo-controlled
trial. J Clin Endocrinol Metab 2005; 90:3179.
44. Gordon, C, Grace, E, Jean Emans, S, et al. Changes in bone turnover markers and
menstrual function after short-term oral DHEA in young women with anorexia
nervosa. J Bone Miner Res 1999; 14:136.
45. Gordon, CM, Grace, E, Emans, SJ, et al. Effects of oral dehydroepiandrosterone on
bone density in young women with anorexia nervosa: a randomized trial. J Clin
Endocrinol Metab 2002; 87:4935.
46. Gordon, CM, Goodman, E, Emans, SJ, et al. Physiologic regulators of bone turnover
in young women with anorexia nervosa. J Pediatr 2002; 141:64.
47. Bravender, T, Robertson, L, et al. Managed care and outpatient eating disorder
program referral patterns: 1996 vs 1991 (abstract). J Adolesc Health 1998; 22.
48. International Academy of Eating Disorders. Position statement on equity in
insurance coverage for eating disorders. www.aedweb.org/disorders.html#healthins.
49. Steinhausen, HC. The outcome of anorexia nervosa in the 20th century. Am J
Psychiatry 2002; 159:1284.
50. Theander, S. Outcome and prognosis in anorexia nervosa and bulimia. J Psychiatr
Res 1985; 19:493.
51. Russell, GF. The prognosis of eating disorders, Springer-Verlag, New York 1991.
p.198.
52. Strober, M, Freeman, R, Morrell, W. The long-term course of severe anorexia
nervosa in adolescents: Survival analysis of recovery, relapse, and outcome
predictors over 10-15 years in a prospective study. Int J Eat Disord 1997; 22:339.
53. van der Ham, T, van Strien, DC, van Engeland, H. Personality characteristics predict
outcome of eating disorders in adolescents: A 4-year prospective study. Eur Child
Adolesc Psychiatry 1998; 7:79.
54. Saccomani, L, Savoini, M, Cirrincione, M, et al. Long-term outcome of children and
adolescents with anorexia nervosa: Study of comorbidity. J Psychosom Res 1998;
44:565.
55. Sullivan, PF, Bulik, CM, Fear, JL, Pickering, A. Outcome of anorexia nervosa: A case-
control study. Am J Psychiatry 1998; 155:939.
56. Keel, PK, Mitchell, JE, Miller, KB, et al. Long-term outcome of bulimia nervosa. Arch
Gen Psychiatry 1999; 56:63.
57. Eckert, ED, Halmi, KA, Marchi, P, et al. Ten-year follow-up of anorexia nervosa:
Clinical course and outcome. Psychol Med 1995; 25:143.
58. Sullivan, PF. Mortality in anorexia nervosa. Am J Psychiatry 1995; 152:1073.
59. Korndorfer, SR, Lucas, AR, Suman, VJ, et al. Long-term survival of patients with
anorexia nervosa: a population-based study in Rochester, Minn. Mayo Clin Proc
2003; 78:278.
60. Sullivan, PF. Discrepant results regarding long-term survival of patients with
anorexia nervosa?. Mayo Clin Proc 2003; 78:273.
61. Stice, E, Shaw, H. Eating disorder prevention programs: a meta-analytic review.
Psychol Bull 2004; 130:206.
62. Taylor, CB, Bryson, S, Luce, KH, et al. Prevention of eating disorders in at-risk
college-age women. Arch Gen Psychiatry 2006; 63:881.
GRAPHICS
Level of care
In general, a given level of care should be considered for patients who meet
one or more criteria under a particular level. These guidelines are not
absolutes, however, and their application requires physician judgment.
* This level of care is most effective if administered for at least 8 hours/day,
5 days/week; less intensive care is demonstrably less effective (101).
If the patient is dehydrated, whole-body potassium values may be low even
if the serum potassium value is in the normal range; determine concurrent
urine specific gravity to assess dehydration.
Determining suicide risk is a complex clinical judgment, as is determining
the most appropriate treatment setting for patients at risk for suicide.
Relevant factors to consider are the patient's concurrent medical conditions,
psychosis, substance abuse, other psychiatric symptoms or syndromes,
psychosocial supports, past suicidal behaviors, and treatment adherence and
the quality of existing physician-patient relationships. These factors are
described in greater detail in the APA's Practice Guideline for the Assessment
and Treatment of Patients With Suicidal Behaviors (84).
Although this table lists percentages of expected healthy body weight in
relation to suggested levels of care, these are only approximations and do
not correspond to percentages based on standardized values for the
population as a whole. For any given individual, differences in body build,
body composition, and other physiological variables may result in
considerable differences as to what constitutes a healthy body weight in
relation to "norms." For example, for some patients, a healthy body weight
may be 110 percent of the standardized value for the population, whereas for
other individuals it may be 98 percent. Each individual's physiological
differences must be assessed and appreciated. For children, also consider the
rate of weight loss. Finally, weight level per se should never be used as the
sole criterion for discharge from inpatient care. Many patients require
inpatient admission at higher weights and should not be automatically
discharged just because they have achieved a certain weight level unless all
other factors are appropriately considered. See text for further discussion
regarding weight.
§ Individuals may experience these thoughts as consistent with their own
deeply held beliefs (in which case they seem to be ego-syntonic and
"overvalued") or as unwanted and ego-alien repetitive thoughts, consistent
with classic obsessive-compulsive disorder phenomenology.
Reproduced with permission from Practice guideline for the treatment of
patients with eating disorders, Third Edition. Am J Psychiatry 2006; 163
Suppl 1:1. Copyright © 2006 American Psychiatric Association.